1. Combined Analysis of Two Parallel Randomized Trials of Sirolimus-Coated and Paclitaxel-Coated Balloons in Coronary In-Stent Restenosis Lesions
- Author
-
Bruno Scheller, Norman Mangner, Muhamad Ali S.K. Abdul Kader, Wan Azman Wan Ahmad, Raban Jeger, Jochen Wöhrle, Tiong Kiam Ong, Houng Bang Liew, Tommaso Gori, Felix Mahfoud, Amin Ariff Nuruddin, Felix Woitek, Imran Zainal Abidin, Carsten Schwenke, Beatrix Schnorr, Rosli Mohd Ali, Bianca Rastoul, Nicole Hollinger, Sebastian Ewen, Michael Böhm, Davor Vukadinovic, Saaraken Kulenthiran, Viktoria Schwarz, Yvonne P. Clever, Axel Linke, Robert Höllriegel, Ephraim Winzer, Stefanie Jellinghaus, Jennifer Hommel, Muhamad Ali bin Sheikh Abdul Kader, Muhammad Dzafir Ismail, Ahmad Syadi Mahmood Zuhdi, Syed Mukhtar Syed Mansor, Christoph Kaiser, Gregor Fahrni, Nicole Gilgen, Andrea Harder-Allgöwer, Margarete Baumgartner, Markovic Sinisa, Olga Smirnova, Alan Yean Yip Fong, Ning Zan Khiew, Asri Bin Said, Yee Ling Cham, Yen Yee Oon, Keng Tat Koh, Chi Yen Voon, Nor Hanim bt Mohd Amin, Wilson anak Johan, Mabelle Wong Fui Jien, Melanie Chong Shu Theng, Tomasso Gori, Al Fazir Omar, Shaiful Azmi, Balachandran Kandasamy, Ahmad Khairuddin Mohamed Yusoff, Salizah Selamat, Maren Kutschera, and Thavin Kumar Mathana Sundram
- Subjects
Coronary Restenosis ,Sirolimus ,Treatment Outcome ,Paclitaxel ,Humans ,Drug-Eluting Stents ,Stents ,Constriction, Pathologic ,Angioplasty, Balloon, Coronary ,Cardiology and Cardiovascular Medicine ,Polychlorinated Biphenyls ,Randomized Controlled Trials as Topic - Abstract
Background: Paclitaxel-coated balloons (PCBs) are a preferred treatment option for coronary in-stent restenosis. To date, data from randomized trials of alternative drug coatings are lacking. The aim of the randomized Malaysian and German-Swiss randomized trials was to investigate a novel sirolimus-coated balloon (SCB) compared with a PCB in in-stent restenosis. Methods: One hundred one patients with drug-eluting stent in-stent restenosis were enrolled in 2 identical randomized trials comparing the novel SCB (SeQuent SCB, 4 μg/mm²) with the clinically proven PCB (SeQuent Please, 3 μg/mm²). Primary end point was angiographic late lumen loss at 6 months. Secondary end points included procedural success, major adverse cardiac events, and individual clinical end points such as stent thrombosis, cardiac death, target lesion myocardial infarction, clinically driven target lesion revascularization, and binary restenosis. Results: Quantitative coronary angiography revealed no differences in baseline parameters. After 6 months, in-segment late lumen loss was 0.25±0.57 mm in the PCB group versus 0.26±0.60 mm in the SCB group. Mean difference between SCB and PCB was 0.01 (95% CI, -0.23 to 0.24). Noninferiority at a predefined margin of 0.35 was shown. Clinical events up to 12 months did not differ between the groups. Conclusions: This first-in man comparison of a novel SCB with a crystalline coating showed similar angiographic and clinical outcomes in the treatment of coronary drug-eluting stent in-stent restenosis compared with PCB. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02996318, NCT03242096.
- Published
- 2022
- Full Text
- View/download PDF